Journal
VACCINE
Volume 27, Issue 45, Pages 6317-6323Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.07.017
Keywords
Influenza H5N1; Oseltamivir resistance; H275Y mutation
Categories
Funding
- MRC [MC_U117584222, MC_U117512708] Funding Source: UKRI
- Medical Research Council [MC_U117512708, MC_U117584222] Funding Source: researchfish
- Medical Research Council [MC_U117512708, MC_U117584222] Funding Source: Medline
Ask authors/readers for more resources
Oseltamivir, one of the two anti-neuraminidase drugs, is currently the most widely used drug against influenza. Resistance to the drug has occurred infrequently among different viruses in response to drug treatment, including A H5N1 viruses, but most notably has emerged among recently circulating A H1N1 viruses and has spread throughout the population in the absence of drug use. Crystal structures of enzyme-drug Complexes, together with enzymatic properties, of mutants of H5N1 neuraminidase have provided explanations for high level oseltamivir resistance due to the common H275Y mutation, with retention of zanamivir susceptibility, and intermediate level resistance due to the N295S mutation. Complementation of enhanced NA activity due to a D344N mutation by the H275Y mutation suggests an explanation for the recent emergence and predominance of oseltamivir-resistant influenza A H1N1 viruses. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available